IQVIA (NYSE:IQV) Upgraded at UBS Group

UBS Group upgraded shares of IQVIA (NYSE:IQV) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks reports.

Other research analysts have also recently issued research reports about the company. HSBC restated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Morgan Stanley increased their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, September 17th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Truist Financial restated a “buy” rating and issued a $329.00 target price (up from $300.00) on shares of IQVIA in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $264.31.

IQVIA Stock Down 0.9%

Shares of NYSE IQV opened at $258.48 on Wednesday. The stock has a market capitalization of $42.55 billion, a PE ratio of 32.07, a P/E/G ratio of 2.23 and a beta of 1.17. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a fifty day moving average of $255.16 and a 200-day moving average of $206.11. IQVIA has a 52-week low of $154.50 and a 52-week high of $277.40.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts anticipate that IQVIA will post 11.56 EPS for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,581 shares of company stock worth $3,796,021 over the last 90 days. Company insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IQV. Korea Investment CORP acquired a new position in shares of IQVIA in the 2nd quarter valued at about $13,918,000. Deutsche Bank AG bought a new position in IQVIA in the second quarter worth about $143,074,000. BlackRock Inc. acquired a new position in IQVIA in the second quarter valued at approximately $2,811,292,000. Focus Partners Advisor Solutions LLC acquired a new position in IQVIA in the second quarter valued at approximately $976,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of IQVIA during the second quarter valued at approximately $1,552,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.